166 related articles for article (PubMed ID: 38586420)
1. A novel tumor mutation-related long non-coding RNA signature for predicting overall survival and immunotherapy response in lung adenocarcinoma.
Chen W; Liao C; Xiang X; Li H; Wu Q; Li W; Ma Q; Chen N; Chen B; Li G
Heliyon; 2024 Apr; 10(7):e28670. PubMed ID: 38586420
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
3. A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma.
Fang X; Huang E; Xie X; Yang K; Wang S; Huang X; Song M
Front Genet; 2022; 13():951311. PubMed ID: 36406130
[No Abstract] [Full Text] [Related]
4. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
5. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
6. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
7. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
Front Genet; 2022; 13():966896. PubMed ID: 36186456
[No Abstract] [Full Text] [Related]
8. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
Front Genet; 2022; 13():862741. PubMed ID: 35368663
[No Abstract] [Full Text] [Related]
9. Identification and validation of tryptophan metabolism-related lncRNAs in lung adenocarcinoma prognosis and immune response.
Gao M; Wang M; Chen Y; Wu J; Zhou S; He W; Shu Y; Wang X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):171. PubMed ID: 38558328
[TBL] [Abstract][Full Text] [Related]
10. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
12. Prognostic signature of lipid metabolism associated LncRNAs predict prognosis and treatment of lung adenocarcinoma.
Zhao J; Li G; Zhao G; Wang W; Shen Z; Yang Y; Huang Y; Ye L
Front Oncol; 2022; 12():986367. PubMed ID: 36387240
[TBL] [Abstract][Full Text] [Related]
13. Identification of the Prognostic Significance of Somatic Mutation-Derived LncRNA Signatures of Genomic Instability in Lung Adenocarcinoma.
Geng W; Lv Z; Fan J; Xu J; Mao K; Yin Z; Qing W; Jin Y
Front Cell Dev Biol; 2021; 9():657667. PubMed ID: 33855028
[No Abstract] [Full Text] [Related]
14. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
15. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
16. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
17. Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma.
Zeng Z; Liang Y; Shi J; Xiao L; Tang L; Guo Y; Chen F; Lin G
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36428951
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
20. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]